This page contains brief details about the drug , it's indication, dosage & administaration, mechanism of action, related brands with strength, warnings and common side effects.

Background and Date of Approval

Lobeglitazone contains the active components Lobeglitazone. It is an antidiabetic drug in the thiazolidinedione class of drugs. It is used to treat type 2 diabetes mellitus (T2DM). It can be used alone or with other diabetes medications, such as metformin or sulfonylureas. It is effective in reducing blood sugar levels and improving HbA1C levels in people with T2DM. It has also been shown to improve lipid profiles and liver function.

Mechanism of Action of undefined

Lobeglitazone is a pure PPAR-alpha agonist, meaning that it binds to and activates the peroxisome proliferator-activated receptor alpha (PPARα) in cells. PPARα is a transcription factor that plays a role in regulating metabolism, including glucose and lipid metabolism. Activating PPARα increases the number of insulin receptors on cells, making them more sensitive to insulin. This leads to a decrease in blood sugar levels.

Uses of undefined

Lobeglitazone is used to treat type 2 diabetes.

undefined Drug administaration and Dosage available

Read the instructions carefully before taking Lobeglitazone. Take them as directed by your doctor. Take it with or without food. This will help to improve absorption. If you experience side effects, stop taking them and talk to your doctor.

Warnings, Precautions and Side Effects of undefined


Lobeglitazone carries important warnings that should be considered. It can cause liver damage, heart failure, pancreatitis, bladder cancer, and an increased risk of bone fractures. It can also cause weight gain, swelling, and dizziness.


You must disclose your full medical history to your healthcare provider, including any underlying health conditions, allergies, and medications you are currently taking. This information will help your healthcare provider assess the suitability and safety of the treatment. Additionally, strictly follow the prescribed dosage and schedule and promptly report any unexpected side effects or changes in your health. If you experience any side effects, talk to your doctor. They can help you determine if the side effects are serious and need to be treated. If you are pregnant, breastfeeding, or have other health conditions, talk to your doctor before taking them. Do not take it if you have liver disease or heart failure.

Side Effects

Lobeglitazone, like any medication, may cause side effects, although not everyone will experience them. Some serious side effects of Lobeglitazone include liver damage, heart failure, pancreatitis (inflammation of the pancreas), bladder cancer, increased risk of bone fractures, and severe allergic reactions. On the other hand, some common side effects include shakiness, sweating, hunger, dizziness, headache, confusion, irritability, slurred speech, difficulty concentrating, and loss of consciousness.

Word Of Advice

Before initiating treatment with lobeglitazone, disclose your medical history with the doctor, including liver disease, pancreas disease, or heart problems.. Close monitoring of liver function and blood sugar monitoring is necessary during and after treatment. Potential drug interactions with other medications should be carefully evaluated, and healthcare providers should be informed about all current medications. Overdose should be avoided, and caution should be taken to reduce the risk of fall as this medication weaken the bone and raises the risk of fracture. Dose adjustments are necessary for patients with severe renal impairment or end-stage renal disease. Pregnancy and breastfeeding considerations should be discussed with a healthcare provider.

Frequently Asked Question


  1. Jaehyun Bae et al., Lobeglitazone: A Novel Thiazolidinedione for the Management of Type 2 Diabetes Mellitus, [Published on April 2021] [ Accessed on 24th June 2023], 
  2. Joonsang Yoo et al., Lobeglitazone, a novel thiazolidinedione, for secondary prevention in patients with ischemic stroke: a nationwide nested case-control study, [Published on May 2023] [Accessed on 24th June 2023], 


The drug information on this page is different from medical advice. It is meant for educational purposes only. For further details, consult your doctor about your medical condition to know if you can receive this treatment.